ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2526

Efficacy of Biological Therapies in Rheumatoid Arthritis: Graphical Modeling of DAS28 Components’ Evolution over Time

G. Avila1, Arnald Alonso1, María América López-Lasanta1, Andrea Pluma-Sanjurjo2, C. Diaz2 and Sara Marsal1, 1Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 2Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologic agents and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Therapeutic Strategies, Biomarkers and Predictors of Outcomes in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose

The wide use of biological therapies (BTs) has clearly modified the therapeutic approach in rheumatoid arthritis (RA). One of the most commonly used tools to measure the efficacy of BTs in RA is the DAS28 score. Little is known about how each of the DAS28 components varies over time. Our aim was to graphically evaluate the evolution of the DAS28 components over time for the most common anti-TNF treatments and to compare them with anti-IL6 therapy.

Methods

222 RA patients treated with BTs during the period between Dec’99 and March’13 were included. The data on the components of DAS28 score were collected from baseline and at every 3 months of therapy. First, we visually analyzed the relative improvement of each variable for each anti-TNF (infliximab (INF), etanercept (ETN), adalimumab (ADA)). Second, we grouped the anti-TNFs and compared their combined evolution to tocilizumab (TCZ). In order to obtain a precise visualization of the changes in time of each of the DAS28 components, we used the radar charts. In this type of multivariate data visualization technique, each one of the components is represented as different circle axes and, at each time point, the mean relative improvement (i.e. percentage of reduction from baseline) for each component is connected by a line

Results

A total of 347 BTs were analyzed (INF=100, ETN=126, ADA=79, TCZ=42). No statistically significant differences were found in the DAS28 changes between the 3 anti-TNFs.  However, when comparing the graphical patterns of these therapies we found different patterns of evolution of the DAS28 components over time (Figure 1). Compared to ADA or INF, ETN had a clearly regular expanding pattern of the improvement. In ADA and INF the relative weight of each DAS28 component at each time period was variable, suggesting a different mode of action for monoclonal therapies 

When we compared the radar charts of the combined anti-TNFs against the anti-IL6 treatment (Figure 2), we found a markedly different pattern of action. While the treatment with anti-TNFs showed rapid and greater improvement in the articular component (i.e. SJC and TJC), the treatment with anti-IL6 showed a higher improvement of the ESR (Figure 2). In both treatments, the physician and patient global assessment showed a similar evolution over time

Conclusion

Using a graphical analysis approach we have identified, for the first time, the differential time patterns of the DAS28 score components for the most commonly used anti-TNF therapies. Combining all anti-TNF therapies into a single entity and comparing to a BT targeting IL6, we have also found key differences in the temporal evolution of each of the DAS28 components. The results of this study are useful to understand the differential mechanisms of action of each treatment and could help to explain the differences observed in clinical trials, meta-analyses or observational studies


Disclosure:

G. Avila,
None;

A. Alonso,
None;

M. A. López-Lasanta,
None;

A. Pluma-Sanjurjo,
None;

C. Diaz,
None;

S. Marsal,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-biological-therapies-in-rheumatoid-arthritis-graphical-modeling-of-das28-components-evolution-over-time/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.